Ptc Therapeutics PTCT Institutional Ownership

Ptc Therapeutics, Inc. (NASDAQ:PTCT) has 383 institutional investors with active 13F positions as of June 2026.

• These investors collectively held 121.7% of Ptc Therapeutics's outstanding shares in June 2026, up from 115.8% in March 2026.
• Their total shares held in PTCT increased 16.31% quarter over quarter, and separately, investors owning Ptc Therapeutics increased 34.86% from a year ago.
• During the quarter, 219 of these 383 funds increased positions in PTCT, 111 reduced exposure, and 53 held steady.
• Combined, these investors held 101.06Mn shares in PTCT for June 2026, up by 14.17Mn shares quarter on quarter, and up 23.22Mn shares year over year.
• BlackRock, Inc. leads ownership in PTCT with 13.96Mn shares as of June 30, 2026, equal to 16.82% of outstanding shares.
• The biggest buyers of Ptc Therapeutics for the quarter ending June 2026 included Jupiter Topco LLC (7.24Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (1.96Mn), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.72Mn), FULLER & THALER ASSET MANAGEMENT, INC. (1.16Mn), BlackRock, Inc. (1.02Mn).
• Leading sellers of Ptc Therapeutics shares for the quarter ending June 2026 were UBS Group AG (1.1Mn), ARMISTICE CAPITAL, LLC (1.0Mn), Toronto Dominion Bank (860.12K), BNP PARIBAS FINANCIAL MARKETS (541.76K), BALYASNY ASSET MANAGEMENT L.P. (439.96K).
• According to Business Quant data, leading holders of PTCT for June 2026 are BlackRock, Inc. (13.96Mn), RTW INVESTMENTS, LP (7.75Mn), Jupiter Topco LLC (7.24Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.93Mn), State Street Corp (4.6Mn), WELLINGTON MANAGEMENT GROUP LLP (4.13Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.74Mn), GEODE CAPITAL MANAGEMENT, LLC (2.21Mn), Toronto Dominion Bank (2.17Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (1.96Mn).